8.2112

0.88% 0.0612

Aurinia Pharmaceuticals Inc (AUPH)

Overview News Price History Option Chain Financials Why AUPH Down? Discussions Forecast Stock Split

Aurinia Pharmaceuticals Inc stock is traded at $8.2112, with a volume of 290.60K. It is up +0.88% in the last 24 hours and up +3.16% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Geographically, it derives maximum revenue from the United States.

Previous Close:

$8.15

Open:

$8.16

24h Volume:

290.60K

Relative Volume:

0.21

Market Cap:

$1.12B

Revenue:

$175.51M

Net Income/Loss:

$-78.02M

P/E Ratio:

-15.49

EPS:

-0.53

Net Cash Flow:

$-34.18M

1W Performance:

+0.39%

1M Performance:

+3.16%

6M Performance:

+16.95%

1Y Performance:

+56.60%

1-Day Range:

$8.0753

$8.285

1-Week Range:

$7.92

$8.39

52-Week Range:

$4.71

$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name

Aurinia Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

250-744-2487

Address

#140, 14315 - 118 AVENUE, EDMONTON, BC

Employee

300

Twitter

@AuriniaPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

AUPH's Discussions on Twitter

Compare AUPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUPH Aurinia Pharmaceuticals Inc	8.22	1.12B	175.51M	-78.02M	-34.18M	-0.53
VRTX Vertex Pharmaceuticals Inc	502.93	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	685.47	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	578.42	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.49	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.97	26.76B	3.32B	-860.46M	-1.04B	-8.32

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-25-21	Reiterated	H.C. Wainwright	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Initiated	BTIG Research	Buy
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy
Dec-16-19	Reiterated	H.C. Wainwright	Buy
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Oct-30-17	Reiterated	H.C. Wainwright	Buy
May-18-17	Reiterated	H.C. Wainwright	Buy
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight
Mar-22-17	Reiterated	FBR & Co.	Outperform
Dec-30-16	Reiterated	H.C. Wainwright	Buy
Aug-17-16	Reiterated	H.C. Wainwright	Buy
Jun-30-16	Initiated	H.C. Wainwright	Buy
May-08-15	Initiated	MLV & Co	Buy

View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

Mar 10, 2025

Aurinia Pharmaceuticals Announces Financial Growth and Pipeline Progress in 2024 - Zenopa

Mar 10, 2025

Mar 09, 2025

Principal Financial Group Inc. Sells 1,325 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

Mar 09, 2025

Mar 08, 2025

Aurinia Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN

Mar 08, 2025

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome - Marketscreener.com

Mar 08, 2025

Mar 07, 2025

Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 - Investing.com

Mar 07, 2025

Commit To Purchase Aurinia Pharmaceuticals At $7, Earn 17.4% Annualized Using Options - Nasdaq

Mar 07, 2025

Mar 06, 2025

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point - Yahoo Finance

Mar 06, 2025

Mar 05, 2025

Aurinia Pharmaceuticals stock climbs on insider buying - MSN

Mar 05, 2025

Mar 04, 2025

Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 - Investing.com Australia

Mar 04, 2025

Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 By Investing.com - Investing.com Canada

Mar 04, 2025

Aurinia Pharmaceuticals CEO Peter Greenleaf sells shares worth $2.87 million - Investing.com India

Mar 04, 2025

Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 By Investing.com - Investing.com South Africa

Mar 04, 2025

Major Investment Alert: Kevin Tang Boosts Stake in Aurinia Pharmaceuticals - TipRanks

Mar 04, 2025

Aurinia Pharmaceuticals’ chief medical officer sells $97,912 in stock - Investing.com

Mar 04, 2025

Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 - Investing.com India

Mar 04, 2025

Aurinia Pharmaceuticals EVP Stephen Robertson sells shares worth $975,223 - Investing.com

Mar 04, 2025

Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - Nasdaq

Mar 04, 2025

Objective long/short (AUPH) Report - Stock Traders Daily

Mar 04, 2025

Mar 03, 2025

LAWSUITS FILED AGAINST ABBV, SDIG and AUPHJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire

Mar 03, 2025

Atria Wealth Solutions Inc. Buys Shares of 15,000 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World

Mar 03, 2025

Mar 02, 2025

Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Simply Wall St

Mar 02, 2025

Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance

Mar 02, 2025

Feb 28, 2025

IFP Advisors Inc Raises Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat

Feb 28, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Feb 28, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong Earnings - MarketBeat

Feb 28, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 28, 2025

Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Feb 28, 2025

Regulatory and Financial Challenges Loom for Aurinia Pharmaceuticals Despite FDA and EC Approvals - TipRanks

Feb 28, 2025

Feb 27, 2025

Aurinia Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks

Feb 27, 2025

Aurinia Pharmaceuticals Reports Balanced Earnings with Growth and Challenges - TipRanks

Feb 27, 2025

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Benzinga India

Feb 27, 2025

Aurinia: Q4 Earnings Snapshot - CT Insider

Feb 27, 2025

Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates - MSN

Feb 27, 2025

Earnings call transcript: Aurinia Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com

Feb 27, 2025

Aurinia Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025

Aurinia Pharmaceuticals Swings to Q4 Earnings, Revenue Rises -February 27, 2025 at 09:26 am EST - Marketscreener.com

Feb 27, 2025

Aurinia Pharmaceuticals Reports Strong Financial Growth in 2024 - TipRanks

Feb 27, 2025

Aurinia Pharmaceuticals Files Form 8-K Indicating Key Corporate Event - TipRanks

Feb 27, 2025

Earnings Flash (AUPH) Aurinia Pharmaceuticals Reports Q4 Revenue $59.9M, vs. FactSet Est of $60.1M - Marketscreener.com

Feb 27, 2025

Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q4 EPS $0.01, vs. FactSet Est of $0.02 Loss - Marketscreener.com

Feb 27, 2025

Aurinia Pharmaceuticals Inc. SEC 10-K Report - TradingView

Feb 27, 2025

Aurinia Pharma earnings missed by $0.02, revenue fell short of estimates - Investing.com UK

Feb 27, 2025

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress - Business Wire

Feb 27, 2025